

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/868,962	06/22/2001	Hassan Jomaa	JOMAA-5(PCT)	9943	
30593	7590 01/12/2005		EXAMINER		
HARNESS,	DICKEY & PIERCE,	COPPINS, JANET L			
P.O. BOX 8910			ART UNIT	PAPER NUMBER	
RESION, VA	RESTON, VA 20195			1626	
			DATE MAILED: 01/12/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/868,962	JOMAA, HASSAN
Office Action Summary	Examin r	Art Unit
	Janet L. Coppins	1626
Th MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespond nce address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days illi apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	rely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. & 133).
Status	•	
 Responsive to communication(s) filed on 20 Second This action is FINAL. Since this application is in condition for allowant closed in accordance with the practice under E 	action is non-final. ace except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 13-24 is/are pending in the application 4a) Of the above claim(s) 20-22 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 24 is/are rejected. 7) ☐ Claim(s) 13-19,23 and 24 is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	n from consideration.	
Application Papers		
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction of the option of the correction of the option of the op	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been receive (PCT Rule 17.2(a)).	on No d in this National Stage
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	PTO-413) te atent Application (PTO-152)

Application/Control Number: 09/868,962

Art Unit: 1626

DETAILED ACTION

Claims 13-24 pending in the instant application.

Information Disclosure Statement

1. Applicants' Information Disclosure Statement (IDS), filed June 22, 2001, has been considered by the Examiner. Please refer to Applicants' copy of the PTO-1449 form submitted herewith.

Response to Restriction Requirement

2. Applicants' election without traverse of Group I, claims 13-19, 23, and 24 (all claims in part) drawn to compounds of Formula I and their pharmaceutical compositions wherein the compound is represented by compounds I-III:

In the response filed September 20, 2004, is acknowledged. Accordingly, claims 20-22 withdrawn from further consideration under 37 CFR 1.142(b) as directed to non-elected inventions.

Status of the claims

5. Claims 13-24 are pending in the application. As a result of the election and the corresponding scope of the invention identified supra, claims 20-22 and the remaining subject matter of claims 13-19, 23, and 24 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected inventions. The withdrawn subject matter is patentably distinct from the elected subject matter as it differs in structure and element and would require

Application/Control Number: 09/868,962 Page 3

Art Unit: 1626

separate search considerations. In addition, a reference that anticipates one group would not render obvious the other groups.

6. In order to advance prosecution, the Examiner recommends canceling the withdrawn claims and subject matter when responding to this Office Action, i.e. claims 20-22 as well as the non-elected subject matter from the remaining claims.

Claim Objections

- 7. Claims 13-19, 23, and 24 objected to as containing non-elected subject matter.
- 8. Claims 1-6, 8-10, 12-19, and 21-24 objected to because of the use of the variable "P" in the structure of formula (Ia). "P" is also the designated abbreviation for phosphorous within the I.U.P.A.C. nomenclature system, and its presence as a variable is confusing in the instant claims.

Claim Rejections - 35 USC \$ 112

- The following is a quotation of the second paragraph of 35 U.S.C. 112:
 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 10. Claim 24 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 24 is directed to a pharmaceutical preparation that, "...contains another pharmaceutical[ly] active substance," which is vague because it is unclear which active substance Applicant is intending to claim. Clarification is requested.

Conclusion

II. In conclusion, claims 13-24 are pending, claims 20-22 are withdrawn, claim 24 is rejected, and claims 13-19, 23, and 24 are objected to.

Art Unit: 1626

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Coppins whose telephone number is 571.272.0680. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on 571.272.0699. The fax phone number for the organization where this application or proceeding is assigned is 571.273.8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Janet L. Coppins January 10, 2005

Joseph K. McKane SPE, Art Unit 1626